RxDoctor Payments Data

Patricia Yun, MD

Dermatology · Long Beach, CANPI 1962468777

Payments from drug & device makers

$2,411in general payments, 2019–2025

Across 34 payments — averaging $70.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$674
  • AbbVie$237
  • UCB, Inc.$214
  • Avanos Medical$209
  • Arcutis Biotherapeutics, Inc.$186
  • Vertex$166
  • plus $725 from 10 others

What the payments were for

  • Food & beverage$2,411100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,411 in reported general payments places this provider in the 50th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$110,363
Medicare patients
439
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab11$153,067
Dupixent SyringeDupilumab13$47,406
OpzeluraRuxolitinib Phosphate12$32,804
Fluorouracil39$2,908
Metronidazole17$879
Clobetasol Propionate29$874
Doxycycline Hyclate13$484
Ketoconazole39$387
Imiquimod15$343
Mupirocin42$245
Fluocinonide13$215
ValacyclovirValacyclovir Hcl30$211
Triamcinolone Acetonide45$209
CiclopiroxCiclopirox Olamine18$175
Prednisone12$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$60$32,80412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,875 dermatology providers in California.

Other dermatology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →